News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
214,520 Results
Type
Article (20208)
Company Profile (104)
Press Release (194201)
Multimedia
Podcasts (55)
Webinars (20)
Section
Business (71426)
Career Advice (844)
Deals (9056)
Drug Delivery (94)
Drug Development (18840)
Employer Resources (149)
FDA (3432)
Job Trends (6147)
News (95401)
Policy (7098)
Tag
2025 Best Places to Work (13)
2026 Best Places to Work (18)
2027 BioCapital Standard (3)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (4)
40 Under 40 (3)
Academia (1548)
Academic (2)
Accelerated approval (30)
ADA (17)
Adcomms (18)
Allergies (53)
Alliances (17380)
ALS (90)
Alzheimer's disease (810)
Antibody-drug conjugate (ADC) (226)
Approvals (3708)
Artificial intelligence (470)
ASCO (104)
Autoimmune disease (167)
Automation (42)
Bankruptcy (53)
Belgium (15)
Best Places to Work (4884)
BIO (33)
Biologics (46)
BIOSECURE Act (12)
Biosimilars (100)
BioSpace Insights (131)
Biotechnology (53)
Bispecific (25)
Bladder cancer (60)
Brain cancer (24)
Breast cancer (299)
Cancer (2222)
Cardiovascular disease (238)
Career advice (787)
Career pathing (50)
CAR-T (138)
CDC (28)
CDMO (73)
Celiac Disease (2)
Cell therapy (384)
Cervical cancer (24)
Clinical research (16331)
Collaboration (1198)
Commercialization (25)
Company closure (1)
Compensation (270)
Complete response letters (28)
COVID-19 (1032)
CRISPR (74)
CRO (5)
C-suite (958)
Cystic fibrosis (65)
Data (3475)
Decentralized trials (3)
Denatured (33)
Depression (68)
Dermatology (86)
Diabetes (228)
Diagnostics (2726)
Digital health (30)
Diversity (10)
Diversity, equity & inclusion (37)
Drug discovery (261)
Drug pricing (58)
Drug shortages (7)
Duchenne muscular dystrophy (109)
Earnings (16502)
Editorial (25)
Employer branding (25)
Employer resources (131)
ESMO (103)
Events (33041)
Executive appointments (760)
Eye disease (9)
FDA (4858)
Fibrodysplasia Ossificans Progressiva (5)
Fragile X (5)
Friedreich's ataxia (14)
Frontotemporal dementia (9)
Funding (1142)
Gene editing (132)
Generative AI (46)
Gene therapy (286)
GLP-1 (412)
Government (1464)
Guidances (137)
Healthcare (5082)
Hematology (78)
HIV (75)
Huntington's disease (35)
Idiopathic pulmonary fibrosis (3)
IgA nephropathy (47)
Immunology and inflammation (92)
Immuno-oncology (38)
Indications (94)
Infectious disease (1188)
Inflammatory bowel disease (104)
Inflation Reduction Act (8)
Influenza (49)
Intellectual property (103)
Interviews (128)
IPO (3666)
IRA (17)
Job creations (1319)
Job search strategy (651)
JPM (28)
Kidney cancer (6)
Kidney disease (58)
Labor market (119)
Layoffs (221)
Leadership (31)
Legal (1187)
Licensing (58)
Liver cancer (30)
Longevity (29)
Lung cancer (272)
Lung diease (11)
Lymphoma (201)
Machine learning (36)
Management (47)
Manufacturing (585)
Marketing (9)
MASH (48)
Medical affairs (5)
Medical device (2770)
Medtech (2848)
Melanoma (64)
Mergers & acquisitions (6047)
Metabolic disorders (533)
Middle East (1)
mRNA (106)
Multiple sclerosis (118)
Multispecific (1)
NASH (9)
Netherlands (26)
Neurodegenerative disease (197)
Neuropsychiatric disorders (32)
Neuroscience (1522)
Neurotech (2)
NextGen: Class of 2026 (2084)
Non-profit (1717)
Now hiring (95)
Obesity (243)
Opinion (163)
Ovarian cancer (74)
Pain (113)
Pancreatic cancer (87)
Parkinson's disease (150)
Partnered (22)
Patents (153)
Patient advocacy (3)
Patient recruitment (227)
Patient selection (23)
Peanut (19)
People (29282)
Peptides (18)
Pharmaceutical (21)
Pharmacy benefit managers (3)
Phase 1 (4758)
Phase 2 (6721)
Phase 3 (6435)
Pipeline (4474)
Policy (139)
Postmarket research (557)
Preclinical (2692)
Press Release (61)
Prostate cancer (116)
Psychedelics (34)
Radiopharmaceuticals (102)
Rare diseases (443)
Real estate (2571)
Recruiting (62)
Regenerative medicine (13)
Regulatory (6473)
Reports (54)
Research institute (1353)
Resumes & cover letters (110)
Rett syndrome (10)
RNA editing (14)
RSV (51)
Saudi Arabia (1)
Schizophrenia (73)
Series A (227)
Series B (136)
Series C (1)
Service/supplier (6)
Sickle cell disease (54)
Special edition (16)
Spinal muscular atrophy (63)
Sponsored (22)
Startups (2059)
State (1)
Stem cells (1)
Stomach cancer (7)
Substance use disorders (4)
Supply chain (50)
Switzerland (8)
Tariffs (18)
Tax incentives (1)
The Weekly (22)
Vaccines (396)
Venture capital (121)
Weight loss (146)
Wet AMD (4)
Women's health (86)
Worklife (22)
Date
Today (17)
Last 7 days (226)
Last 30 days (1173)
Last 365 days (10576)
2026 (9763)
2025 (9651)
2024 (11360)
2023 (12946)
2022 (15515)
2021 (17632)
2020 (16239)
2019 (14943)
2018 (10796)
2017 (10276)
2016 (10149)
2015 (10838)
2014 (7985)
2013 (6919)
2012 (7347)
2011 (7527)
2010 (7014)
Location
Africa (335)
Alabama (38)
Alaska (4)
Arizona (126)
Arkansas (4)
Asia (12114)
Australia (2093)
California (5148)
Canada (1528)
China (558)
Colorado (272)
Connecticut (161)
Delaware (235)
Europe (31663)
Florida (724)
Georgia (153)
Hawaii (3)
Idaho (12)
Illinois (364)
India (60)
Indiana (405)
Iowa (21)
Japan (310)
Kansas (53)
Kentucky (17)
Louisiana (14)
Maine (12)
Maryland (458)
Massachusetts (4089)
Michigan (160)
Minnesota (256)
Mississippi (6)
Missouri (62)
Montana (6)
Nebraska (10)
Nevada (58)
New Hampshire (17)
New Jersey (1512)
New Mexico (19)
New York (1595)
North Carolina (793)
North Dakota (12)
Northern California (2827)
Ohio (175)
Oklahoma (14)
Oregon (28)
Pennsylvania (815)
Puerto Rico (15)
Rhode Island (20)
South America (394)
South Carolina (16)
Southern California (1858)
Tennessee (103)
Texas (762)
United States (18656)
Utah (106)
Vermont (1)
Virginia (139)
Washington D.C. (33)
Washington State (419)
West Virginia (1)
Wisconsin (116)
Wyoming (1)
214,520 Results for "alimera sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Alimera Sciences Reports First Quarter 2024 Results
Alimera Sciences, Inc. today announced financial results for the first quarter of 2024.
May 14, 2024
·
11 min read
Business
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2023.
March 7, 2024
·
16 min read
BioMidwest
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved, on May 22, 2024, inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan.
June 4, 2024
·
1 min read
Deals
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc. announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
June 24, 2024
·
17 min read
Business
Alimera Sciences Reports Third Quarter 2023 Results
Alimera Sciences, Inc. today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
October 26, 2023
·
14 min read
Business
Alimera Sciences Reports Second Quarter 2023 Results
Alimera Sciences, Inc. today announced financial results for the second quarter of 2023.
August 10, 2023
·
11 min read
BioMidwest
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 20, 2024
Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of Mr. Todd Wood as President of U.S. Operations of the Company, Mr. Elliot Maltz as Chief Financial Officer of the Company, and five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved certain inducement grants under the Alimera Sciences, Inc.
March 20, 2024
·
4 min read
Funding
OrbiMed raises two new life sciences funds worth $3B with one aiming for Asia
The sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.
October 16, 2026
·
1 min read
·
Tristan Manalac
Eye disease
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
September 28, 2026
·
1 min read
·
Gabrielle Masson
Business
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it will report first quarter financial results on May 14, 2024, prior to the market open.
April 30, 2024
·
1 min read
1 of 21,452
Next